Neurobiology of Aging
Volume 28, Issue 4 , Pages 548-554 , April 2007

MR features of the substantia innominata and therapeutic implications in dementias

  • Haruo Hanyu

      Affiliations

    • Department of Geriatric Medicine, Tokyo Medical University, 6-7-1 Nishishinjuku Shinjuku-ku, Tokyo 160-0023, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 3 3342 6111; fax: +81 3 3342 2305.
    • ,
  • Soichiro Shimizu

      Affiliations

    • Department of Geriatric Medicine, Tokyo Medical University, 6-7-1 Nishishinjuku Shinjuku-ku, Tokyo 160-0023, Japan
    • ,
  • Yuriko Tanaka

      Affiliations

    • Department of Geriatric Medicine, Tokyo Medical University, 6-7-1 Nishishinjuku Shinjuku-ku, Tokyo 160-0023, Japan
    • ,
  • Kentaro Hirao

      Affiliations

    • Department of Geriatric Medicine, Tokyo Medical University, 6-7-1 Nishishinjuku Shinjuku-ku, Tokyo 160-0023, Japan
    • ,
  • Toshihiko Iwamoto

      Affiliations

    • Department of Geriatric Medicine, Tokyo Medical University, 6-7-1 Nishishinjuku Shinjuku-ku, Tokyo 160-0023, Japan
    • ,
  • Kimihiko Abe

      Affiliations

    • Department of Radiology, Tokyo Medical University, Tokyo, Japan

Received 29 July 2005 ,Revised 5 December 2005 ,Accepted 11 February 2006.

References 

  1. Black S, Roman GC, Geldmacher DS, Salloway S, Hecker J, Burns A, et al. the Donepezil 307 Vascular Dementia Study Group Efficacy and tolerability of donepezil in vascular dementia. Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke. 2003;34:2323–2332
  2. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, et al. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm. 2000;59(Suppl.):23–30
  3. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. Lancet. 2002;359:1283–1290
  4. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198
  5. Forstl H, Burns A, Luthert P, Cairns N, Lewy R. The Lewy-body variant of Alzheimer's disease. Clinical and pathological findings. Br J Psychiatry. 1993;162:385–392
  6. Gottfries CG, Blennow K, Karlsson I, Wallin A. The neurochemistry of vascular dementia. Dementia. 1994;4:163–167
  7. Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, et al. Cerebral blood flow in dementia. Arch Neurol. 1975;32:632–637
  8. Hanyu H, Asano T, Sakurai H, Tanaka Y, Takasaki M, Abe K. MR analysis of the substantia innominata in normal aging, Alzheimer's disease, and other types of dementia. Am J Neuroradiol. 2002;23:27–32
  9. Hanyu H, Tanaka Y, Shimizu S, Sakurai H, Iwamoto T, Abe K. Differences in MR features of the substantia innominata between dementia with Lewy bodies and Alzheimer's disease. J Neurol. 2005;252:482–484
  10. Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology. 1990;40:1–8
  11. Hughes CP, Berg L, Danziger WL, Cohen LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566–572
  12. Kalaria RN, Ballard K. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord. 1999;13:S115–S123
  13. Kato T, Hirano A, Katagiri T, Sasaki H, Yamada S. Neurofibrillary tangle formation in the nucleus basalis of Meynert ipsilateral to a massive cerebral infarct. Ann Neurol. 1988;23:620–623
  14. Langlais PJ, Thal L, Hansen L, Galasko D, Alford M, Masliah E. Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies. Neurology. 1993;43:1927–1934
  15. Liberini P, Valerio A, Memo M, Spano P. Lewy-body dementia and responsiveness to cholinesterase inhibitors: a paradigm for heterogeneity of Alzheimer's disease?. Trends Pharmacol Sci. 1996;17:155–160
  16. Levy R, Eagger S, Griffiths M, Perry E, Honavar M, Dean A, et al. Lewy bodies and response to tacrine in Alzheimer's disease. Lancet. 1994;343:176
  17. Lippa CF, Smith TW, Perry E. Dementia with Lewy bodies: choline acetyltransferase parallels nucleus basalis of pathology. J Neural Transm. 1999;106:525–535
  18. Lovestone S, Graham N, Howard R. Guidelines on drug treatments for Alzheimer's disease. Lancet. 1997;350:232–233
  19. Mann DMA, Yates PO, Marcyniuk B. The nucleus basalis of Meynert in multi-infarct (vascular) dementia. Acta Neuropathol (Berl). 1986;71:332–337
  20. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113–1124
  21. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet. 2000;356:2031–2036
  22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939–944
  23. Mesulam M, Siddique T, Cohen B. Cholinergic denervation in a pure multi-infact state. Observations on CADASIL. Neurology. 2003;60:1183–1185
  24. Pearson RCA, Gatter KC, Powell TPS. Retrograde cell degeneration in the basal nucleus in monkey and man. Brain Res. 1983;261:321–326
  25. Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE. Neurotransmitter enzyme abnormalities in senile dementia. J Neurol Sci. 1977;34:247–265
  26. Perry EK, Haroutunian V, Davis KL, Levy R, Lantos P, Eagger S, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport. 1994;5:747–749
  27. Perry E, Ziabreva I, Perry R, Aarsland D, Ballard C. Absence of cholinergic deficits in “pure” vascular dementia. Neurology. 2005;64:132–133
  28. Querfurth HW, Allam GJ, Geffroy MA, Schiff HB, Kaplan RF. Acetylcholinesterase inhibitors in dementia with Lewy bodies: results of a prospective pilot trial. Dement Geriatr Cogn Disord. 2000;11:314–321
  29. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250–260
  30. Rossor MN, Garrett NJ, Johnson AL, Mountjoy CQ, Roth M, Iversen LL. A post-mortem study of the cholinergic and GABA systems in senile dementia. Brain. 1982;105:313–330
  31. Samuel W, Caligiuri M, Galasko D, Lacro J, Marini M, Mcclure FS, et al. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry. 2000;15:794–802
  32. Sands LP, Katz I, Schneider L. Assessing individual patients for cognitive benefits from acetylcholinesterase inhibitors. Alzheimer Dis Assoc Disord. 1999;13:26–33
  33. Sasaki M, Ehara S, Tamakawa Y, Takahashi S, Tohgi H, Sakai A, et al. MR anatomy of the substantia innominata and findings in Alzheimer disease: a preliminary study. Am J Neuroradiol. 1995;16:2001–2007
  34. Selden NR, Gitelman DR, Salamon-Maruyama N, Parrish TB, Mesulam M-M. Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain. 1998;121:2249–2257
  35. Tanaka Y, Hanyu H, Sakurai H, Takasaki M, Abe K. Atrophy of the substantia innominata on magnetic resonance imaging predicts response to donepezil treatment in Alzheimer's disease patients. Dement Geriatr Cogn Disord. 2003;16:119–125
  36. Tiraboschi P, Hansen LA, Alford M, Sabbagh MN, Schoos B, Masliah E, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology. 2000;54:407–411
  37. Tiraboschi P, Hansen LA, Alford M, Merdes A, Masliah E, Thal LJ, et al. Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Arch Gen Psychiatry. 2002;59:946–951
  38. Tohgi H, Abe T, Kimura M, Saheki M, Takahashi S. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J Neural Transm. 1996;103:1211–1220
  39. Tohgi H, Homma A, Imai Y, Udaka F, Takeda M, Nishimura T, et al. Long-term safety and efficacy of acetylcholinesterase inhibitor E2020 in patients with Alzheimer-type dementia—52-week open label study. Clin Eval. 2000;28:97–126(abstract in English)
  40. Tomimoto H, Ohtani R, Shibata M, Nakamura N, Ihara M. Loss of cholinergic pathways in vascular dementia of the Binswanger type. Dement Geriatr Cogn Disord. 2005;19:282–288
  41. Vinters HV, Ellis WG, Zarow C, Zaias BW, Jagust WJ, Mack WJ, et al. Neuropathologic substrates of ischemic vascular dementia. J Neuropathol Exp Neurol. 2000;59:931–945
  42. Wallin A, Alafuzoff A, Carlsson A, Eckernas S-A, Gottfries C-G, Karlsson I, et al. Neurotransmitter deficits in a non-multi-infarct category of vascular dementia. Acta Neurol Scand. 1989;79:397–406
  43. Wallin A, Sjogren M, Blennow K, Davidsson P. Decreased cerebrospinal fluid acetylcholinesterase in patients with subcortical ischemic vascular dementia. Dement Geriatr Cogn Disord. 2003;16:200–207
  44. Wesnes KA, McKeith IG, Ferrara R, Emre M, Del Ser T, Spano PF, et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomized placebo-controlled international study using the cognitive drug research computerized assessment system. Dement Geriatr Cogn Disord. 2002;13:183–1192
  45. Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, et al. the Donepezil 308 Study Group Donepezil in vascular dementia. A randomized, placebo-controlled study. Neurology. 2003;61:479–486

PII: S0197-4580(06)00075-3

doi: 10.1016/j.neurobiolaging.2006.02.009

Neurobiology of Aging
Volume 28, Issue 4 , Pages 548-554 , April 2007

Article Tools

* Image Usage & Resolution